公开(公告)号：WO2020167619A1

公开(公告)日：2020-08-20

申请号：PCT/US2020/017408

申请日：2020-02-10

申请人： MERCK SHARP & DOHME CORP. ,  LOBODA, Andrey ,  LUNCEFORD, Jared K. ,  ZHANG, Chunsheng ,  NEBOZHYN, Michael ,  CRISTESCU, Razvan ,  AYERS, Mark D. ,  MCCLANAHAN, Terrill K. ,  MA, Hua

发明人： LOBODA, Andrey ,  LUNCEFORD, Jared K. ,  ZHANG, Chunsheng ,  NEBOZHYN, Michael ,  CRISTESCU, Razvan ,  AYERS, Mark D. ,  MCCLANAHAN, Terrill K. ,  MA, Hua

IPC分类号： C12Q1/6886 ,  C07K16/30 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00

摘要： The invention relates to a stromal/EMT/TGFβ signature that is predictive of patient response to treatment with a PD-1 antagonist, wherein the stromal/EMT/TGFβ signature comprises five or more genes selected from Table 1 disclosed herein. More specifically, a lower stromal/EMT/TGF-β score is associated with favorable response to a PD-1 antagonist in a patient with cancer. Also provided are methods of treating a cancer patient with a PD-1 antagonist that were identified as positive for the stromal/EMT/TGFβ biomarker of the invention. The disclosure also provides methods and kits for testing tumor samples for the biomarkers.

公开(公告)号：WO2022241470A1

公开(公告)日：2022-11-17

申请号：PCT/US2022/072310

申请日：2022-05-13

申请人： THE GENERAL HOSPITAL CORPORATION ,  CARAVAN, Peter ,  NING, Yingying ,  MA, Hua ,  SHUVAEV, Sergey ,  AKAM, Eman

发明人： CARAVAN, Peter ,  NING, Yingying ,  MA, Hua ,  SHUVAEV, Sergey ,  AKAM, Eman

IPC分类号： C07D255/02 ,  A61K49/06 ,  C07D257/02 ,  A61B6/037 ,  C07D401/12 ,  C07D417/12 ,  C07D471/08

摘要： Disclosed herein are methods of molecular magnetic resonance (MR) imaging and positron emission tomography using extracellular probes that target extracellular allysine aldehyde and act as a noninvasive biomarker of fibrogenesis with high sensitivity and specificity in detecting fibrogenesis, for example, in rodent models and human fibrotic tissues.

公开(公告)号：WO2021091747A1

公开(公告)日：2021-05-14

申请号：PCT/US2020/057814

申请日：2020-10-29

申请人： MERCK SHARP & DOHME CORP. ,  AYERS, Mark, D. ,  CRISTESCU, Razvan ,  LOBODA, Andrey ,  LUNCEFORD, Jared, K. ,  MA, Hua ,  MCCLANAHAN, Terrill, K. ,  NEBOZHYN, Michael ,  ZHANG, Chunsheng

发明人： AYERS, Mark, D. ,  CRISTESCU, Razvan ,  LOBODA, Andrey ,  LUNCEFORD, Jared, K. ,  MA, Hua ,  MCCLANAHAN, Terrill, K. ,  NEBOZHYN, Michael ,  ZHANG, Chunsheng

IPC分类号： C07K16/28 ,  C12Q1/68 ,  G06F19/20

摘要： The invention relates to (i) an angiogenesis gene signature and (ii) a monocytic myeloid-derived suppressor cell (mMDSC) gene signature that are each predictive of patient response to treatment with a PD-1 antagonist, wherein the angiogenesis signature comprises five or more genes. More specifically, a lower angiogenesis score is associated with favorable response to a PD-1 antagonist in a patient with cancer. Similarly, a lower mMDSC score is associated with favorable response to a PD-1 antagonist in a patient with cancer. Also provided are methods of treating a cancer patient with a PD-1 antagonist that were identified as either (i) positive for the angiogenesis gene signature biomarker of the invention or (ii) positive for the mMDSC gene signature biomarker of the invention.